Tredegar Corp (TG) Stock News

Hercules Capital (HTGC) gained 1.16% to $16.55, outperforming the S&P 500's 0.47% decline on October 8, 2026. However, the stock has declined 7.1% over the past month. Analysts expect Q3 EPS of $0.49 (flat year-over-year) and revenue of $142.2 million (+2.98% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 8.39, trading at a premium to its industry average of 7.28.

Hercules Capital (HTGC) closed at $16.74, down 1.18%, underperforming the S&P 500's 0.73% gain. The stock has declined 4.4% over the past month. The company is expected to report unchanged EPS of $0.49 with projected revenue growth of 2.98% year-over-year. For the full year, earnings are forecast to grow 2.09% to $1.95 per share. HTGC holds a Zacks Rank #3 (Hold) with a Forward P/E of 8.69, trading at a premium to its industry average of 7.49.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

The TGCT market is projected to grow from USD 326 million in 2025 to USD 3.34 billion by 2036, driven by a 20.8% CAGR. CSF1R-targeted therapies like pexidartinib (TURALIO) and vimseltinib (ROMVIMZA) are transforming treatment, with emerging candidates including pimicotinib and emactuzumab expected to capture significant market share. The US remains the largest market, with surgery continuing as the primary first-line treatment for localized disease while systemic therapies expand for advanced cases.

MediciNova reported topline results from its Phase 2 MN-001-NATG-202 trial evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD in type 2 diabetes patients. The drug showed statistically significant increases in HDL-C and HDL-P, significant early triglyceride reduction at Week 4, and numerical improvements in body weight and liver fat. MN-001 demonstrated a favorable safety profile, though the company indicated a larger study is needed to further evaluate efficacy.

Proxy advisory firm ISS recommended Empery Digital stockholders vote for two of ATG Capital's four director nominees and withhold support from two incumbent directors. ISS found the board improperly rejected ATG Capital's nominations and criticized the board's functioning as 'less than robust,' supporting ATG Capital's case for boardroom change ahead of the October 14 annual meeting.

Hercules Capital (HTGC) closed down 1.45% and underperformed the S&P 500. The specialty finance company is expected to post steady EPS of $0.49 with revenue growth of 2.98% year-over-year. For fiscal year 2026, earnings are projected to grow 2.09% to $1.95 per share with revenue increasing 8.56% to $578.1 million. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 8.83, trading at a premium to its industry average of 7.98.

Canadian National Railway (CNI) successfully shipped its first unit train from Total Grain Marketing's expanded grain elevator in Lis, Illinois on September 16, 2026. The expansion adds 3.1 million bushels of storage capacity and increases receiving capacity to 85,000 bushels per hour, enabling unit trains to be loaded in just eight hours. CNI moved a record 2.50 MMT of grain in August 2026, exceeding the previous August record, reflecting strong demand and efficient operations as the new crop year begins.

While Wall Street analysts maintain a bullish average brokerage recommendation (ABR) of 1.61 for B2Gold with 64.3% Strong Buy ratings, the Zacks Rank assigns the stock a #3 (Hold) rating. The article cautions that brokerage recommendations often suffer from positive bias due to institutional vested interests, and notes that B2Gold's unchanged consensus earnings estimate of $0.49 suggests the stock may perform in line with the broader market in the near term.

Target (TGT) emerges as the superior value option compared to Costco (COST) based on valuation metrics and earnings outlook. TGT holds a Zacks Rank #2 (Buy) with a forward P/E of 15.32 and Value grade of B, while COST has a Zacks Rank #3 (Hold) with a forward P/E of 39.73 and Value grade of D.

A Delaware Chancery Court ruled that Empery Digital's board breached its fiduciary duties by improperly rejecting ATG Capital's director nomination notice in an attempt to prevent stockholder choice. The court found the board's actions were preclusive and designed to entrench incumbents, validating ATG Capital's nominees for the October 14 annual meeting. ATG Capital, which owns 4.5 million shares, is urging stockholders to vote for its four nominees.

Target's stock has surged 34.4% over six months, significantly outperforming peers and the broader market, driven by improving business trends, stronger consumer engagement, and solid digital performance. The company raised fiscal 2026 net sales guidance to around 5% and adjusted EPS guidance to $9.90-$10.90. Trading at 15.86x forward earnings—below industry average but above its one-year median—Target receives a Zacks Rank #2 (Buy) rating, with analysts suggesting existing investors hold while prospective investors gradually build positions.

Globus Medical (GMED) and Integer (ITGR) are compared as potential value investments in the medical instruments sector. GMED emerges as the superior value option with a Zacks Rank #1 (Strong Buy) rating, lower forward P/E ratio of 14.88 versus ITGR's 20.68, and a Value grade of B compared to ITGR's C grade. GMED also shows stronger earnings estimate revisions and more favorable valuation metrics across multiple indicators.

A comparison of Target (TGT) and Costco (COST) in the retail discount stores sector reveals that Target presents a better value opportunity. Target has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 15.72, and a Value grade of B. Costco, with a Zacks Rank of #3 (Hold), has a higher forward P/E of 41.75 and a Value grade of D, making it less attractive for value investors.

TG Therapeutics shares have gained 15.1% since its last earnings report in early September 2026. While the company beat revenue expectations with $240.3M (up 70.3% YoY) driven by strong Briumvi sales, it missed EPS estimates at $0.05 vs. $0.41 expected. The company raised its 2026 revenue guidance to ~$950M. However, analyst estimates have trended downward since the report, and the stock received a Zacks Rank #3 (Hold) with poor Growth and Momentum scores, suggesting limited upside ahead.

MGIC Investment Corporation (MTG) reported strong Q2 2026 results with new insurance written rising 8.5% to $17.8 billion and insurance in force increasing 2.6% to $304.8 billion. The company maintains solid capital resources with $2.7 billion in PMIERs excess and benefits from strong cure activity and favorable policy performance. While credit normalization is occurring gradually, management expects manageable delinquency trends. MTG stock is rated Zacks Rank #1 (Strong Buy) and trades at a discount to industry peers.

UMH Properties secured a new $10.2 million Fannie Mae mortgage at 6.03% fixed rate for a 267-site community through Wells Fargo. After paying off a $2.8 million existing mortgage, the company generated $7.4 million in additional proceeds to deploy toward acquisitions, expansions, rental homes, and debt repayment. The community has been improved from 69% to 95% occupancy since acquisition in 2014.

In a comparison of two medical instruments stocks, Globus Medical (GMED) emerges as the superior value option over Integer (ITGR). GMED holds a Zacks Rank #1 (Strong Buy) with a Value grade of B, featuring a lower forward P/E ratio of 16.86 and PEG ratio of 1.35. ITGR carries a Zacks Rank #3 (Hold) with a Value grade of C, posting a higher forward P/E of 20.55 and PEG ratio of 2.96. Based on valuation metrics and earnings outlook, GMED is positioned as the more attractive choice for value investors.

A class action lawsuit has been filed against BitGo Holdings, Inc. (NYSE: BTGO) alleging that the company's IPO offering documents were negligently prepared and contained false or misleading statements. The lawsuit claims BitGo understated risks related to declining digital asset prices and lacked a reasonable basis for statements about its financial performance and business prospects. Investors who purchased BitGo securities between January 22, 2025 and May 13, 2026 have until August 7, 2026 to apply to be appointed as lead plaintiff.

Schall, Brown & Schwartz LLP announced a class action lawsuit against BitGo Holdings, Inc. (NYSE: BTGO) for alleged violations of securities laws. The firm claims BitGo made false and misleading statements during its January 2026 IPO, downplaying risks associated with declining digital asset prices while promoting positive financial performance. Shareholders who purchased shares between January 22, 2025 and May 13, 2026 are encouraged to participate, with an August 7, 2026 deadline.

A securities class action lawsuit has been filed against BitGo Holdings, Inc. (NYSE: BTGO) alleging that offering documents and statements made during its January 2026 IPO and through May 2026 contained material misstatements and omissions. Specifically, the lawsuit claims BitGo understated risks from declining digital asset prices and made false statements about its financial performance and business prospects. Investors who purchased BTGO securities have until August 7, 2026 to become lead plaintiffs.

A class action lawsuit has been filed against BitGo Holdings, Inc. alleging that the company made false and misleading statements in its January 2026 IPO offering documents. The lawsuit claims BitGo understated risks related to declining digital asset prices and lacked a reasonable basis for statements about its financial performance and business prospects. Investors who purchased BitGo securities between January 22, 2025 and May 13, 2026 have until August 7, 2026 to apply as lead plaintiff.

Halper Sadeh LLC, an investor rights law firm, is investigating three major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations involve Supernus Pharmaceuticals' sale to Indivior, Integer Holdings' acquisition by KKR, and Bowhead Specialty Holdings' sale to American Family Mutual Insurance. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

A class action lawsuit has been filed against BitGo Holdings, Inc. alleging that the company's IPO offering documents were negligently prepared and contained false or misleading statements. The lawsuit claims BitGo understated risks related to declining digital asset prices and lacked a reasonable basis for statements about its financial performance and business prospects. Investors who purchased BitGo securities between January 22, 2025 and May 13, 2026 have until August 7, 2026 to apply as lead plaintiff.

A securities class action lawsuit has been filed against BitGo Holdings, Inc. for allegedly making false and misleading statements regarding the risks posed by declining digital asset prices to its business and financial performance. The lawsuit covers investors who purchased BitGo stock during its January 22, 2026 IPO and through May 13, 2026. BitGo's stock declined significantly following disappointing financial results announcements in March and May 2026.

A securities class action lawsuit has been filed against BitGo Holdings, Inc. alleging that offering documents and statements made during its January 2026 IPO and through May 2026 contained material misstatements and omissions. Specifically, the lawsuit claims defendants understated risks from declining digital asset prices and made false statements about the company's financial performance and business prospects. Investors who purchased BitGo securities during the class period have until August 7, 2026 to become lead plaintiffs.

A shareholder class action lawsuit has been filed against BitGo Holdings, Inc., alleging that the company's IPO offering documents were negligently prepared and contained false or misleading statements. The lawsuit claims BitGo understated risks related to declining digital asset prices and lacked a reasonable basis for statements about financial performance. The deadline to apply as lead plaintiff is August 7, 2026.

Pomerantz LLP has filed a class action lawsuit against BitGo Holdings, Inc. and certain officers for violations of federal securities laws. The lawsuit alleges that BitGo's IPO offering documents and public statements contained materially false and misleading information regarding the company's exposure to digital asset price declines. BitGo's stock fell significantly following disappointing earnings announcements in March and May 2026, with the company reporting substantial net losses and declining margins.

Rosen Law Firm announces an August 7, 2026 deadline for investors to join a securities class action lawsuit against BitGo Holdings, Inc. (BTGO). The lawsuit alleges that IPO registration documents and statements contained false or misleading information regarding digital asset price risks and their impact on BitGo's financial performance and business prospects.

Rosen Law Firm is notifying investors in BitGo Holdings, Inc. (NYSE: BTGO) and GRAIL, Inc. (NASDAQ: GRAL) of ongoing securities class action lawsuits. BitGo investors who purchased shares during the IPO on January 22, 2026 or between January 22 and May 13, 2026 are urged to act before the August 7, 2026 lead plaintiff deadline. The lawsuit alleges that offering documents contained false statements regarding BitGo's risk exposure to declining digital asset prices and overstated business prospects. GRAIL investors have an August 4, 2026 deadline for the class action period covering May 13, 2025 to February 19, 2026.